Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.
Serving US Federal and NGO clients.
Integrated services that cover planning, management, execution and analysis.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
Offering solutions that combine in-house expertise and proprietary innovative technology.
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Digital solutions that increase efficiency in clinical trials by driving site performance.
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
The cost pressures on drug development are driving the search for savings. Results from an industry survey by ICON and Pharma Intelligence.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
23 July, 2018
31 July, 2018
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
ICON & Informa survey of industry executives
Read the views of 3 Senior Pharma Executives on how their organisations are approaching innovation
Explore how mapping stakeholder value can help drive profitable device development programmes in increasingly value driven markets
How to Stay Current on Immuno-Oncology
ICON and Practice Fusion extend partnership to provide live Active Patient EHR data for clinical records.
Aspects of Parkinson’s Disease studies that sponsors should bear in mind as they plan their clinical trials.
Site performance ignited: Digital solutions increase efficiency in clinical trials by driving site performance.
Successful clinical trial recruitment requires a thorough
understanding of the target patient profile, and a key
factor within this profile is patient motivation.
The US Food & Drug Administration (FDA) amended requirements
for the acceptance of clinical data cllected outside the US
to support medical device submissions.
The opportunity for blockchain in healthcare and clinical
Late phase studies are ripe for digitalisation, although not
always in the same ways as Phase II and III programs.
Learn how to use biostatistics using RMST in Oncological
trials to improve clinical outcomes
NASH ranks among the world’s great emerging health threats
ICON has developed a lab logistics program to reduce costs
Late phase research, once the exception, is becoming the rule. Some post marketing evidence needs can be met with virtual studies, DtP and cyber studies.
There is an increasing demand from sponsors for technology and
data-driven solutions to improve site selection, study start-
up and patient recruitment.